Peptide Therapy Legal Status and What Your Consent Must Disclose

Where peptide therapy actually stands with the FDA

Start with the fact that most clinics soften. BPC-157, TB-500 and thymosin beta-4, CJC-1295, ipamorelin, epitalon, semax, KPV, MOTS-c and similar compounds are not FDA-approved drugs. No manufacturer has taken them through the approval process, no approved labeling exists, and there is no agency-reviewed dossier of efficacy and safety for any indication.

That is not the same as saying they are illegal, and it is not the same as saying they are unsafe. It means the safety and efficacy question has not been answered by the body that normally answers it, and the patient is entitled to know that before consenting.

A small number of peptides sit differently. Sermorelin acetate was approved as Geref and later withdrawn from sale, with FDA determining in the Federal Register that the withdrawal was not for reasons of safety or effectiveness. Semaglutide and tirzepatide are approved drugs with approved labeling; the compounded versions of them are a separate regulatory question with its own rules. Grouping all of these under one word, "peptides," is where consent forms usually start going wrong.

Unapproved new drug versus off-label: the distinction your consent must make

Off-label prescribing is the use of an FDA-approved drug for an indication, population, dose or route the label does not cover. It is lawful, common, and well understood in medicine. Roughly a fifth of prescriptions written in the United States are off-label.

An unapproved new drug is a different animal. It has never been approved for anything, so there is no label to be off. Prescribing it is not "off-label use," and describing it that way in a consent form misstates the situation to the patient in a way that a plaintiff's attorney will enjoy reading aloud.

The practical consequence is that your consent language cannot borrow the comfortable framing of off-label prescribing. It has to say that the substance has not been approved by the FDA for any use, that its safety and effectiveness for the patient's purpose have not been established through the approval process, and that long-term effects are not known.

The 503A bulks list, Category 2, and what changed in 2024 through 2026

Because these substances have no approved product, patients receive them as compounded preparations. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy may compound from a bulk drug substance only if the substance has an applicable USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List that FDA maintains.

That list is not finished, so FDA runs an interim policy that sorts nominated substances into three categories. Category 1 covers substances FDA has evaluated without identifying significant safety risks, and FDA does not intend to take action against compounders using them while evaluation continues. Category 2 covers substances FDA has identified as presenting significant safety risks, and FDA would take enforcement action against a compounder using them. Category 3 covers substances nominated without enough supporting information to evaluate.

The sequence since 2023 is worth understanding, because clinic marketing has repeatedly misread it.

In 2023, FDA placed a group of peptides into Category 2, effectively closing 503A compounding for them. BPC-157 was among the substances affected, alongside ipamorelin and CJC-1295, and the practical result was that compliant pharmacies stopped supplying them.

In September 2024, FDA removed five substances from Category 2, including CJC-1295 and ipamorelin acetate, because the parties who nominated them withdrew the nominations. Removal on a withdrawn nomination is an administrative event, not a safety clearance, and it does not establish that a substance meets the criteria for compounding.

What happened next to those two is instructive, because it is the part clinics rarely mention. Both were referred to the advisory committee, which reviewed ipamorelin in October 2024 and CJC-1295 in December 2024 and voted against recommending either one for the 503A Bulks List. Neither was included in the July 2026 review. Coming off Category 2 bought them a hearing, not a place on the list.

In April 2026, FDA removed twelve more peptide bulk substances from Category 2, again following withdrawn nominations. The group included BPC-157, TB-500, epitalon, semax, KPV, MOTS-c, DSIP, LL-37, dihexa acetate, PEG-MGF, melanotan II and injectable GHK-Cu. FDA scheduled a Pharmacy Compounding Advisory Committee meeting to consider whether some of them belong on the 503A Bulks List.

At that meeting on July 23 and 24, 2026, the committee voted to recommend six of the seven peptides under review for inclusion on the list: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. Emideltide, also known as DSIP, was the only rejection. The margins were narrow, with abstentions recorded in every vote: BPC-157, KPV and TB-500 each passed 8-6, MOTS-c 7-5, semax 8-5 and epitalon 7-5. In each case the committee voted to recommend a substance that FDA's own review staff had concluded did not meet the agency's evidentiary standard for the list.

Here is the part that clinic marketing has largely skipped. The committee is advisory. Its votes do not bind FDA, they do not place anything on the list, and they do not make compounding lawful. Formal placement requires FDA to publish a notice of proposed rulemaking, run a public comment period and issue a final rule, a sequence that commonly takes twelve months or more. Until that final rule issues, these substances are not on the 503A Bulks List and are not authorized bulk substances for compounding. A practice telling patients that BPC-157 is "FDA cleared" or "now approved" is making a claim the record does not support.

What a peptide consent form must disclose

A peptide consent has to carry the eight standard elements of informed consent and then go further, because the regulatory status is itself a material risk.

The standard elements: the patient's diagnosis or the clinical reason for treatment, the nature and purpose of the proposed treatment, the material risks and side effects, the expected benefits and the honest likelihood of achieving them, reasonable alternatives including doing nothing, the risks of declining, an opportunity to ask questions, and a voluntary dated signature from a patient with capacity.

The peptide-specific additions are what most template forms omit:

The substance is not approved by the FDA for any indication, and its safety and effectiveness have not been established through FDA review. State it in plain words, not in a footnote.

The preparation is compounded, which means it has not undergone FDA premarket review for safety, effectiveness or manufacturing quality, and potency or purity may vary between pharmacies and between lots.

The specific substance, the compounding pharmacy that prepared it, the pharmacy's state license, the lot number, the route of administration, the dose and the frequency.

That long-term effects are unknown, that clinical trial evidence in humans is limited or absent for the patient's intended use, and that published claims often rest on animal or laboratory data rather than human outcomes.

Known and theoretical risks, including injection site reactions, infection, allergic and hypersensitivity reactions, and any substance-specific concerns such as effects on growth hormone axis regulation for secretagogues or theoretical concerns about promoting the growth of existing malignancy.

Alternatives that were considered, including approved therapies, and why they were or were not chosen.

The regulatory status disclosure that the status of compounded peptides is actively changing, that a substance available today may become unavailable, and that the clinic will notify the patient if that occurs.

For any patient who is an athlete subject to testing, that many of these substances are prohibited under anti-doping rules.

Disclosure is protective precisely because it is unflattering. A consent that says the treatment is well established and safe, when the record says neither, is the document that loses a case. A consent that says clearly that the evidence is limited and the patient chose to proceed anyway is the document that wins one.

Sourcing, and why "research use only" is not a defense

The most serious exposure in this field is not consent language. It is supply.

Peptides purchased from research chemical suppliers, overseas vendors or online marketplaces cannot lawfully be administered to patients. FDA has taken the position in warning letters that a "research use only" or "not for human consumption" disclaimer carries no weight when the product is marketed and sold for human use, and dosing information on a website or in a sales conversation is treated as evidence of intended use.

There is also no compounding exemption a clinic can claim for itself. Compounding is a pharmacy activity performed by a licensed pharmacy against a patient-specific prescription, or by a registered outsourcing facility. A clinic reconstituting bulk powder in the treatment room is manufacturing without registration.

The workable path is narrow: a patient-specific prescription written after a documented examination, dispensed by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, for a substance that pharmacy may lawfully compound. If no compliant pharmacy will supply a substance, that is a signal about the substance rather than an invitation to find a different supplier.

The documentation around the consent

The consent is one file in a set. The good-faith examination record shows a prescriber evaluated the patient and identified a clinical rationale. The chart note records the substance, pharmacy, lot number, expiration, dose, route, sites and patient response. The pharmacy record shows a licensed source and a patient-specific prescription. The follow-up note records tolerance, response and any adverse events. The adverse event log captures anything unexpected, together with the reporting decision.

Reconsent when the substance changes, when the dose changes materially, or when the regulatory status of what the patient is receiving shifts. A consent signed in 2024 does not describe the landscape a patient faces in 2026.

The bottom line

Peptide therapy is legally workable but only on a narrow path: a documented exam, a patient-specific prescription, a licensed compounding pharmacy, and a consent form that tells the truth about approval status. The July 2026 advisory committee votes are a meaningful signal for BPC-157, TB-500, KPV, MOTS-c, epitalon and semax, but they are recommendations rather than authorizations, and nothing about them makes these substances FDA-approved drugs. Write the consent to survive being read aloud in a deposition, keep the sourcing chain documented, and reconsent when the picture moves, because it has moved twice already.

Frequently asked questions

Is peptide therapy legal in the United States?

Prescribing a peptide is legal when the substance may lawfully be compounded and dispensed by a licensed pharmacy against a valid patient-specific prescription, following a documented examination. What is not legal is buying peptides from a research chemical supplier and administering them to patients, because that is administering an unapproved new drug regardless of what the vial label says.

Is BPC-157 approved for compounding now?

Not yet. FDA removed BPC-157 from Category 2 of the interim 503A bulks list in April 2026 after its nomination was withdrawn, and the Pharmacy Compounding Advisory Committee voted in July 2026 to recommend it for inclusion on the 503A Bulks List. That vote is advisory and not binding, and FDA has not completed the formal placement, so the substance is not yet an authorized bulk substance for 503A compounding.

Is prescribing a peptide the same as off-label prescribing?

No, and the distinction matters for your consent language. Off-label prescribing means using an FDA-approved drug for an unapproved indication, which is a recognized part of the practice of medicine. Most wellness peptides have never been approved for any indication, which makes them unapproved new drugs rather than off-label uses, and your consent should say so in those terms.

Related templates